Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer

Current Opinion in Urology

Volumn 17, Issue 5, 2007, Pages 352-357

  Hendricksen, Kees ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; Nonmuscle invasive; Therapy; Urothelial cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; APAZIQUONE; BCG VACCINE; DOXORUBICIN; EOQUIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CONSERVATIVE TREATMENT; CYSTECTOMY; DEVICE; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; THERMOCHEMOTHERAPY; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NEOPLASM INVASIVENESS; PATIENT SELECTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34548443495     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3281c55f2b     Document Type: Review

References (42)

1. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66:4-34.
2. Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol 2002; 41:105-112.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-477. A simple scoring system presented in this report enables determination of probabilities for recurrence and progression of bladder urothelial cell carcinoma.
4. Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 1996; 155:1233-1238.
5. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149:749-752.
6. Bouffioux C, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995; 153:934-941.
7. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171:2186-2190.
8. Beretta G. Bladder cancer. In: Mitomycin C. Turin, Italy: Edizioni Minerva Medica; 2001. pp. 170-181.
9. Onrust SV, Wiseman LR, Goa KL. Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 1999; 15:307-333.
10. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol 1996; 156:962-966.
11. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169:90-95.
12. Hendricksen K, Kiemeney LA, Caris CTM, et al. Three schedules of adjuvant intravesical epirubicin in patients with nonmuscle invasive bladder cancer: a comparative study. European Urology Suppl 2007; 6:60. This is the largest multicentre study of epirubicin yet performed; it found no difference between three different treatment schedules.
13. van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166:476-481.
14. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996; 156:1934-1940; discussion.
15. Witjes JA, van der Heijden AG, Vriesema JL, et al. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45:182-186.
16. Laufer M, Ramalingam S, Schoenberg MP, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21:697-703.
17. Gontero P, Casetta G, Maso G, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46:339-343.
18. Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology 2005; 65:65-69.
19. Campodonico F, Canepa G, Capponi G, et al. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res 2005; 25:2381-2384.
20. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24:2729-2734. This study reports on the efficacy of gemcitabine in a group that is, for the urologist, rather difficult to manage, namely high-risk BCG-refractory patients.
21. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005; 66:726-731.
22. Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 1991; 3:199-206.
23. Li D, Gan Y, Wientjes MG, et al. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors. J Urol 2001; 166:2500-2505.
24. van der Heijden AG, Verhaegh G, Jansen CF, et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 2005; 173:1375-1380.
25. van der Heijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 2006; 176:1349-1353. The ablative efficacy of apaziquone in this study is among the highest histologically and cytologically obtained complete responses (67%) of all available intravesical therapies.
26. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66:108-125.
27. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970.
28. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163:1124-1129.
29. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003; 44:429-434.
30. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006; 49:790-797. This article provides a good overview of all aspects related to patients failing to respond to BCG therapy.
31. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675.
32. Kiemeney LA, Witjes JA, Verbeek AL, et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 1993; 67:806-812.
33. Schrier BP, Hollander MP, van Rhijn BW, et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45:292-296.
34. Colombo R, Da Pozzo LF, Lev A, et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996; 155:1227-1232.
35. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21:4270-4276.
36. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46:65-71.
37. Witjes JA, Hendricksen K, Gofrit ON, et al. Intravesical hyperthermia and mitomycin-C for (BCG-refractory) carcinoma in situ of the urinary bladder. European Urology Suppl 2007; 6:60. Patients with mostly BCG refractory carcinoma in situ were treated with thermochemotherapy. A remarkably high complete response rate was achieved (94%), with low risk for recurrence at 1-year follow up (30%).
38. Colombo R, Brausi M, Da PL, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion. Eur Urol 2001; 39:95-100.
39. Di Stasi SM, Giannantoni A, Stephen RL, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170:777-782.
40. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7:43-51. The authors report a significantly lower progression rate for patients treated with sequential BCG and MMC/EMDA, as compared with BCG alone, which is very promising.
41. Waidelich R, Stepp H, Baumgartner R, et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001; 165:1904-1907.
42. Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003; 61:338-341.